LinkedIn emplea cookies para mejorar la funcionalidad y el rendimiento de nuestro sitio web, así como para ofrecer publicidad relevante. Si continúas navegando por ese sitio web, aceptas el uso de cookies. Consulta nuestras Condiciones de uso y nuestra Política de privacidad para más información.
LinkedIn emplea cookies para mejorar la funcionalidad y el rendimiento de nuestro sitio web, así como para ofrecer publicidad relevante. Si continúas navegando por ese sitio web, aceptas el uso de cookies. Consulta nuestra Política de privacidad y nuestras Condiciones de uso para más información.
This template can be used as a starter file to give updates for project milestones.
Sections Sections can help to organize your slides or facilitate collaboration between multiple authors. On the Home tab, under Slides, click Section, and then click Add Section.
Notes Use the Notes pane for delivery notes or to provide additional details for the audience. You can see these notes in Presenter View during your presentation. Keep in mind the font size (important for accessibility, visibility, videotaping, and online production)
Coordinated colors Pay particular attention to the graphs, charts, and text boxes. Consider that attendees will print in black and white or grayscale. Run a test print to make sure your colors work when printed in pure black and white and grayscale.
Graphics, tables, and graphs Keep it simple: If possible, use consistent, non-distracting styles and colors. Label all graphs and tables.
Figure 1 Selected Pharmacologic Features of Cannabinoids Showing Antiseizure Effects in Preclinical Models. The exact targets that mediate the antiseizure effects of cannabinoids are unknown. Several cannabinoids are known to bind to multiple targets in the central nervous system and exert effects at nanomolar or low micromolar concentrations. These targets include transient receptor potential cation channel, subfamily V, members 1, 2, and 3 (TRPV1-3), glycine receptor α (α3GlyR), peroxisome proliferator-activated receptor gamma (PPAR-γ), calcium-gated ion channel (Cav3 ion channel), and diacylglycerol lipase α (DAGL-α). There are conflicting results from multiple studies on the effects of Δ9-tetrahydrocannabinol on G-protein-coupled receptor (GPR) 55. CB1R and CB2R denote cannabinoid receptor types 1 and 2, 5-HT the serotonin receptors 5-hydroxytryptophan type 1A and 3A, TRPA transient receptor potential cation channel, subfamily A, and TRPM transient receptor potential cation channel, subfamily M. Adapted from Cascio and Pertwee9 and Pertwee and Cascio.10
Table 1 Clinical Trials, Case Series, and Case Reports on Cannabinoids in the Treatment of Epilepsy.
What is the project about? Define the goal of this project Is it similar to projects in the past or is it a new effort? Define the scope of this project Is it an independent project or is it related to other projects?
* Note that this slide is not necessary for weekly status meetings
Symposium Investor Roadshow November 2015 - MGC Pharmaceuticals
MGC Pharmaceuticals (MGC), is a medical and
cosmetic cannabis company with licenses to grow,
extract and sell Cannabis Sativa in Slovenia, inside
MGC holds unique genetics consisting of an
exclusive strain of “Cannabis Sativa” which comprises
of very low Tetrahydrocannabinol (THC) at below
0.3% and a very high Cannabidiol (CBD) content of
MGC is currently developing its own product range
of cosmetic and over-the-counter (OTC) medical
products in partnership with its JV partner, Dr. M.
Capitalising on “Israeli Medical
Cannabis IP” – world leaders in
the production and delivery of
medical cannabis products
$2.7 million initial capital
Some wolves, their habitat destroyed and overwhelmed by human
pressures, turn to snorting quack...
Selected Pharmacologic Features of Cannabinoids Showing Antiseizure Effects in Preclinical
Friedman D, Devinsky O. N Engl J Med 2015;373:1048-1058
MGC Pharma- Key Points Of Difference
Sources: Credit Suisse – Market Research, ArcView Group,
• Positioned in the rapidly growing medical cannabis market (worth US$2.7bn globally) and
cosmetic market (estimated at US$270 b globally in 2014)
• Focused strategy to enter the Australian market following the favourable regulatory shift by the
• Unique genetics from exclusive strain of Cannabis Sativa comprising very low THC levels (<0.32)
and high CBD levels (>10%) - yielding higher amounts of CBD by 4x against existing hemp crops
• Fully Licensed Operation established in Slovenia to Grow, Extract and Import/Export into EU
• Highly experienced team with commercial success in the medical cannabis industry in Israel - a
world leader in the industry
• Multiple revenue streams, with significant uplift from full production capacity to be realized in
• $60m off take agreement for MGC’s initial CBD production starting mid 2016
• MGC cosmetic and OTC medical products – first sales and revenues end 2015
Wealth of industrial cannabis
Sativa (Hemp) managing and
extraction experience, he
shares Mr. Segev’s vision of
building a large scale
European extraction facility
and has the necessary skills
to establish and run a
successful growing operation
and extraction facility. He has
business contacts in the
Previously CEO of Israel’s
second largest licensed
Medical Cannabis company,
Cann Pharmaceuticals. Led
the company to fully
commercialize from startup
position . Founded MGC
Pharmaceuticals to expand
into the huge European
market for cannabinoids in the
MC Industry Leaders- Expertise and Experience
Co-Founder, President &
A prominent practising
cardiologist and host of weekly
radio 2UE program: Healthy
Living. He has his own medical
practice and specialises in all
aspects of echocardiography.
Other area of expertise is in the
field of preventative cardiology.
He has published seven
books on preventative health
and regularly lectures both
nationally and internationally.
Dr Ross Walker
Non-Executive Director and
Head of Advisory Board
Joins upon completion of
from CBD off-take
agreements and cosmetic
and OTC medical
Opportunity to leverage
growing and extraction
expertise in the Australian
MGC has a business model which closes the supply chain –demand exists for the end
products and MGC is now working towards establishing the supply of the raw material.
• Development of Cannabis Strains in Slovenian
• Plantation and harvesting of crops in outdoor facility in
• Crops to be processed on site at Slovenian facility and
• Targeting 60% purity CBD resin
• MGC has the capability to process other crops on site
• Sell CBD Extract into:
• Wholesale markets – other off-takes in pipeline
• Off-take with Natura JV to utilise in cosmetic products.
Medical Cannabis could be legally available in
Australia as early as 2016
MGC Australian Strategy
MGC to be first in line to exploit scalable commercial opportunities in Australia for
CBD based expertise and products
Appointment of Dr Ross Walker as Non-Executive
Director and Head of Strategic Advisory Board.
Collaboration with University of Sydney Business
School on research and commercial opportunities in
Leverage Dr Ross Walker’s significant contacts in
Australia and potential for access to distribution
channels for MGC’s CBD products.
Take advantage of tax incentives from new Federal
Government innovation and research push.
Global Market Opportunity – Medical Cannabis
• Cannabinoids are legal in 23 U.S states
and the medical cannabis market is
estimated to be worth USD$2.7 billion
globally in 2014 and US$10 billion by
• In Canada the market for medical
cannabis is expected to grow
significantly, from $144m in 2014
• Common diseases for which
Cannabinoids have shown high levels of
efficacy have combined sales of
+US$300 million to date
Sources: ArcView Group, The HIA, Statista
1. 100,000,000 Performance Shares upon MGC securing an off-take agreement to sell commercial quantities of CBD resin that contains a minimum
purity of 50%, and achieving first revenues of at least 1m Euro within three years, as detailed in ASX announcement dated 18 May 2015.
Note- On completion of acquisition, MGC vendor securities will be escrowed pursuant to Ch 1&2 of the ASX Listing Rules
Current issued capital 507,586,552 Nil 53,500,000 $2.0m
Shares to be issued to consultants
and prospectus shares
3,846,700 Nil Nil Nil
Underwriting Options to be issued Nil Nil 20,000,000 Nil
MGC vendor consideration
200,000,000 100,000,0001 Nil Nil
Total 711,433,252 100,000,0001 73,500,000 ~$2.0m
Cannabidiol (CBD) – Global Potential
Scientific and clinical studies indicate that CBD could be effective in easing symptoms of a
wide range of difficult-to-control conditions, including:
1. CBD has demonstrated neuro-protective effects, and its anti-cancer potential is currently being explored at several academic
research centers in the U.S. and other countries.
2. Impacts pathways in the body, which control pain and support the immune system, thereby delivering significant medicinal
benefits in the treatment of chronic pain
CBD- Treatment of Epilepsy
-Despite over 20 different anti-seizure
drugs available, 30% of patients with
epilepsy still experience seizures
-A recent study of 137 patients with
severe, refractory epilepsy on maximal
standard anti-convulsant therapy, given
a purified CBD extract, had a 54%
reduction in seizure frequency
Clinical Trials, Case Series, and Case Reports on Cannabinoids in the Treatment of Epilepsy.
Friedman D, Devinsky O. N Engl J Med 2015;373:1048-
CBD- Treatment of Chronic Pain
-7 % of Australians suffer some form of chronic
-There are increasing issues with the over-
prescription of narcotic analgesics & significant
side effects of non steroidal anti-inflammatory
-A number of studies are showing a significant
reduction in pain & improvements in sleep
parameters in a variety of CBD based products
CBD- Treatment of Cancer
3 Areas of Potential Benefit
1) Chemotherapy induced
2) Cancer pain
3) Cancer growth & spread
CBD- Treatment of MS and Alzheimers
3 Areas of Potential Benefit
2) Neuropathic pain
3) Central Nervous System
1)MULTIPLE THERAPUETIC BENEFITS
FOR MEDICAL CANNABIS IN THE FORM
2)AN EXTENSIVE RANGE OF SKIN CARE,
COSMETIC & OTHER OTC PRODUCTS
This presentation has been prepared by Erin Resources Limited to be renamed MGC Pharmaceuticals Ltd (“Company”). It does not purport to contain all the
information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this
presentation, or any information provided in connection with it, as financial advice, financial product advice or advice relating to legal, taxation or investment
No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy,
completeness or reasonableness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this
presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecasts or projections set out in
This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and
make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or
supplement the information at any time in its absolute discretion (without incurring any obligation to do so).
Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other
person or entity arising out of this presentation including pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian
Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian
state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or
liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.
Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available
information and should not be used in isolation as a basis to invest in the Company.
This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company.
Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are based on certain assumptions, which may not be met
or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number
of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its
directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of
return will be achieved.
Given the risks and uncertainties that may cause the Company’s actual future results, performance or achievements to be materially different from those
expected, planned or intended, recipients should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company
does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.
This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any securities in the United States or to, or for the account or
benefit of any “US person” as defined in Regulation S under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not
be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United
States or to any US person without being so registered or pursuant to an exemption from registration including an exemption for qualified institutional buyers.
Media and Capital Partners
+61 438 008 616
ERIN soon to be MGC Pharmaceuticals
+61 8 9389 2000